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Are old-old patients with major depression more
likely to relapse than young-old patients during
continuation treatment with escitalopram?
Constantine G Lyketsos1*, Emmanuelle Weiller2, Cornelius Katona3, Phillip Gorwood4
Abstract
Background: Escitalopram has shown efficacy and tolerability in the prevention of relapse in elderly patients with
major depressive disorder (MDD). This post-hoc analysis compared time to relapse for young-old patients (n = 197)
to that for old-old patients (n = 108).
Method: Relapse prevention: after 12-weeks open-label treatment, remitters (MADRS ≤12) were randomised to
double-blind treatment with escitalopram or placebo and followed over 24-weeks. Patients were outpatients with
MDD from 46 European centers aged ≥75 years (old-old) or 65-74 years of age (young-old), treated with
escitalopram 10-20mg/day. Efficacy was assessed using the Montgomery Åsberg Depression Rating Scale (MADRS).
Results: After open-label escitalopram treatment, a similar proportion of young-old patients (78%) and old-old
patients (72%) achieved remission. In the analysis of time to relapse based on the Cox model (proportional hazards
regression), with treatment and age group as covariates, the hazard ratio was 4.4 for placebo versus escitalopram
(c2-test, df = 1, c2= 22.5, p < 0.001), whereas the effect of age was not significant, with a hazard ratio of 1.2 for
old-old versus young-old (c2-test, df = 1, c2 = 0.41, p = 0.520). Escitalopram was well tolerated in both age groups
with adverse events reported by 53.1% of young-old patients and 58.3% of old-old patients. There was no
significant difference in withdrawal rates due to AEs between age groups (c2-test, c2 = 1.669, df = 1, p = 0.196).
Conclusions: Young-old and old-old patients with MDD had comparable rates of remission after open-label
escitalopram, and both age groups had much lower rates of relapse on escitalopram than on placebo.
Background
Older adults with depression often have several chronic
disorders and are more treatment-resistant [1]. These
patients also have a higher risk of medication side
effects, due to co-morbid medical conditions and age-
associated changes in organ function. Moreover, a
higher risk for drug-drug interactions may cause them
to terminate treatment prematurely.
Second generation antidepressants [selective serotonin
reuptake inhibitors (SSRIs) and serotonin-noradrenaline
reuptake inhibitors (SNRIs)] are recommended as first-
line treatments in clinical practice guidelines and are
most commonly prescribed for depressive disorders in
older patients [2]. Nevertheless, until 2003, only one
large placebo-controlled trial of a non-tricyclic antide-
pressant, marketed in the US, in outpatients 60 years of
age or older with major depressive disorder had been
published [3]. The first trials of second-generation anti-
depressants, including a large study of patients aged
75 years and above treated with citalopram, reported no
advantage over placebo [4-6] or small drug-placebo dif-
ferences [3,7], hence the clinical value of these agents in
treating older depressed adults was uncertain.
A later meta-analysis of 10 randomised placebo-con-
trolled trials in depressed patients aged 60 years and
older concluded that antidepressants are more effective
than placebo, although effects were modest and variable
[8]. A major limitation was that the average age of
patients in these trials ranged from 60 to 72 years, with
only a small number over 75. Late-life spans a broad
age range and can be divided into young-old (60-74
years), and old-old (≥75 years). Among the old-old,
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antidepressant treatment may be especially complicated
because of the high frequency and severity of co-morbid
conditions, such as cognitive impairment or heart
disease.
In addition to being well tolerated as an antidepres-
sant in older persons [4,5,9-11], escitalopram is effective
in preventing relapse of MDD in patients ≥65 years [12].
The latter study, as well as open-label data, suggests that
escitalopram is safe and well tolerated in the long-term
treatment of older patients with MDD [9].
In order to compare the efficacy and safety of escitalo-
pram in the old-old with the young-old, we undertook a
secondary analysis of a published clinical trial [12]. The
primary aim was to compare the effect of escitalopram
in preventing relapse of MDD among young-old and
old-old patients. A secondary objective was to compare
the initial response to open-label escitalopram in these
two age groups. We hypothesized that old-old and
young-old patients on escitalopram would have compar-
able benefits with regard to prevention of relapse and
initial remission.
Methods
The original study was conducted in 46 centers in 7
European countries from October 2003 to May 2005, in
accordance with the principles of Good Clinical Practice
[13] and the Declaration of Helsinki [14] applicable at
the time of the study. The study was approved by the
relevant local ethics committees and all patients gave
written informed consent for participation. The methods
and main results of the principal study have been
described [12].
Design Overview
This relapse prevention study started with a 12-week
open-label treatment period that was followed by a
24-week, randomised, double blind treatment period
(Figure 1). During the initial open-label period, outpati-
ents aged at least 65 years received escitalopram 10mg/
day during the first week; the dose could be increased
to 20mg/day at Week 2, based on the clinical judgement
of the investigator. Subsequently the dose remained con-
stant for the remaining open label period. At the end of
the 12-week open-label period, patients who achieved
remission, defined by a Montgomery Åsberg Depression
Rating Scale [15] (MADRS) score ≤12, were eligible for
randomisation to either continue escitalopram at their
last fixed dose of 10 or 20mg/day, or to switch to
placebo in a 1:1 ratio. Patients randomised to placebo
who were on 20 mg/day escitalopram during the open
period received 10 mg/day escitalopram for the first
week (Week 13) before receiving placebo for the
remainder of the study. Non-remitters left the study and
were treated at the physician’s discretion.
During the 24-week double-blind period (until taper at
Week 36), study investigators regularly evaluated relapse
symptoms. Relapse was defined either as a MADRS total
score ≥22 at a single visit, or an unsatisfactory treatment
effect (lack of efficacy), as judged by the local investiga-
tor. In order to capture all patients who could be con-
sidered to have relapsed, this definition was extended in
a sensitivity analysis to include patients who met the
DSM-IV criteria for MDE or who attempted suicide.
Patients who relapsed were withdrawn from the study
and were contacted for a safety follow-up assessment
4 weeks later.
Patients
Psychiatrists recruited patients in private practice or
hospital outpatient clinics. Those eligible for study were
outpatients with a primary diagnosis of MDD (assessed
by psychiatrists using the Mini International Neuropsy-
chiatric Interview) [16], moderate or severe, according
to DSM-IV-TR criteria [17], and who gave informed
consent. Inclusion and exclusion criteria are described
in detail by Gorwood et al. [12]. Patients were required
to have a MADRS score ≥22 and an MMSE score ≥24
at entry. Patients with severe or unstable medical
co-morbid diseases were excluded.
Medication treatment
Study medications were tablets for oral administration
of identical appearance, taste and smell. The oxalate salt
of escitalopram, or a placebo, was used in the tablets.
After the open-label period, eligible patients were
assigned to escitalopram or placebo according to a com-
puter-generated randomisation list drawn up by
H. Lundbeck A/S. Details of the randomisation were
unknown to any of the investigators and were contained
in a set of sealed opaque envelopes. At each study
Period I
Acute treatment
(12-week, open label)
Period II
Continuation treatment
(24-week, double blind)
W12 W36 W37
Escitalopram fixed dose (10 or 20 mg) 
PlaceboTAPER
TAPER
Remitters only
MADRS ≤ 12
Escitalopram 10 or 20 mg
Flexible dose for first 6-weeks
N=254
N=102
N=95
W0W-1
Run in
Relapse N=30
MADRS ≥ 22 
or lack of efficacy
MADRS ≥ 22
W13
Relapse N=7
MADRS ≥ 22 
or lack of efficacy
young-old
Escitalopram fixed dose (10 or 20 mg) 
PlaceboTAPER
TAPEREscitalopram 10 or 20 mg
Flexible dose for first 6-weeks
N=151
N=50
N=58
Relapse N=6
MADRS ≥ 22 
or lack of efficacy
Relapse N=20
MADRS ≥ 22 
or lack of efficacy
MADRS ≥ 22
old-old
Figure 1 Study design.
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center, sequentially enrolled patients were assigned the
lowest randomisation number available in blocks of
four. All study personnel and participants were blinded
to treatment assignment for the duration of the study.
Assessments
After baseline assessment of efficacy measures, efficacy
and tolerability parameters were assessed after 2, 4, 6, 8,
and 12 weeks of open-label treatment. For patients ran-
domised to double-blind treatment, efficacy and toler-
ability parameters were assessed 1, 2, and 4 weeks after
randomisation, and then every 4 weeks until the last
dose of double-blind treatment (Week 24 of double
blind, also Week 36 of the full study).
Efficacy assessments at baseline and each follow-up
visit included the MADRS, Clinical Global Impression -
Severity of illness (CGI-S) and Clinical Global Impres-
sion-Improvement of illness (CGI-I) [18]. The primary
analysis of efficacy was the time to relapse from the
start date of double-blind treatment. Prior to the study,
all investigators attended a joined MADRS and CGI
rating session chaired by an experienced research
psychiatrist.
The tolerability and safety evaluations were based on
spontaneously reported adverse events (AEs), vital signs,
body weight, and physical examination.
Statistical Analysis
To provide more clinically useful information in the age
contrast during the open label period, patient response
was pre-defined as at least 50% improvement from base-
line in the MADRS total score, as was remission
(MADRS ≤12). Complete remission (MADRS ≤5) was
defined post hoc. All efficacy analyses in the double-
blind period were conducted on the modified intent-to-
treat (ITT) dataset, consisting of all randomised patients
who took at least one dose of trial medication in the
double-blind treatment period, using the last observa-
tion carried forward (LOCF) approach to impute miss-
ing data. Comparisons between age groups during the
open-label period were performed using analysis of
covariance (ANCOVA) with age group and country as fac-
tors, and with the score at randomisation as a covariate.
The pre-defined primary efficacy analysis [12] used a
two-tailed log-rank test to compare the time to relapse
for patients treated with escitalopram versus placebo,
using SAS version 9.1 as statistical software. In addition,
Kaplan-Meier survival curves were produced and Cox
proportional hazards models were estimated to assess
the effect of several variables on time to relapse. A
c
2-test was used to compare the crude proportions of
relapsed patients. In the current study, the focus was on
the effect of age - comparing the old-old (patients aged
≥75 years) versus the young-old (65 to 74 years), using a
Cox model and logistic regression, with treatment and
age group as covariates. The appropriateness and
robustness was studied by investigating the possible
effect of country and of country-by-treatment interac-
tion. The results from analyses with center as a covari-
ate were in line with that of the primary analysis and
revealed no “outliers” among countries or centers.
Results
Patient Characteristics
Of the 405 patients who received open-label escitalo-
pram, 254 were aged 65-74 years (young-old) and 151
were ≥75 years of age (old-old). The baseline character-
istics of these two groups were similar, apart from
differences in mean age at MDD onset. Also, the old-old
group had a slightly higher percentage of women,
slightly more ongoing general medical diseases per
patient, and more patients with a first episode of MDD
(Table 1). There were no clinically relevant differences
in the severity of depression as measured by MADRS or
CGI-S between young-old and old-old patients (Table 1).
Comparison by age in the 12-week open label period
Withdrawals
During the open-label period, 39 out of 254 young-old
patients (15.4%) withdrew, 25 due to AEs (9.8%)
(Figure 2). For old-old patients, 33 out of 151 patients
(21.9%) withdrew during the 12-week open-label period,
21 due to AEs (13.9%). The difference in withdrawal
rates was not statistically significant between the two
age groups (logistic regression, Wald c2 = 1.8484, df = 1,
p = 0.174). There was also no significant difference
Table 1 Baseline patient characteristics
Patients aged
65-74 yearsa
(n = 254)
Patients aged
≥75 years
(n = 151)
Mean age in years (SD) 69 (3) 79 (4)
Sex (n, % women) 193 (76%) 120 (79%)
BMI in kg/m2 (SD) 26.5 (4.2) 25.8 (4.0)
Mean duration of current
MDE in weeks (SD)
16.3 (15.1) 16.6 (16.5)
Mean age at MDD onset
in years (range)
62 (18-74) 71 (12-90)
First episode (n, %) 67 (26.4%) 51 (33.8%)
Co-morbid diseases/patient
(mean ± SD)
3.1 (2.1)* 3.7 (2.3)
MADRS total score
(mean ± SD)
31.1 (5.0) 30.9 (4.1)
CGI-S (mean ± SD) 4.9 (0.7) 4.8 (0.7)
a all patients were at least 65 years of age.
BMI: body mass index, CGI-S: Clinical Global Impression - Severity of illness,
MADRS: Montgomery-Åsberg Depression Rating Scale, MDE: major depressive
episode; SD: standard deviation * p < 0.05 versus patients aged ≥75 years.
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between age groups in withdrawal rates due to AEs (chi-
square test, c2 = 1.55, df = 1, p = 0.212).
Efficacy
Of the 254 young-old patients entering open-label treat-
ment, 215 achieved remission (78%) and 197 were ran-
domly assigned to treatment with escitalopram (n =
102) or placebo (n = 95) (Figure 2). The young-old
patients had a mean baseline MADRS total score of 31.1
± 5.0 at entry, which decreased over time to 9.0 ± 9.5
(LOCF). Similarly, of the 151 old-old patients entering
the open-label period, 118 achieved remission (72%) and
108 were randomly assigned to treatment with escitalo-
pram (n = 50) or placebo (n = 58) (Figure 2). These
patients had a mean baseline MADRS total score of
30.9 ± 4.1 at inclusion, which decreased over time to
10.9 ± 9.8 (LOCF).
A similar proportion of young-old (83.1%, n = 211)
and old-old (77.5%, n = 117) patients responded (ITT,
LOCF, Fisher’s Exact test, p = 0.339,) or achieved remis-
sion (young old: 81.9%, n = 208; old-old 75.5%, n = 114)
(ITT, LOCF, Fisher’s Exact test, p = 0.128) by week 12.
A significantly higher proportion of young-old patients
achieved complete remission (MADRS ≤5) at week 12
(young old: 48.4%, n = 123; old-old 35.1%, n = 53) (Fisher’s
Exact test, p = 0.010) (ITT, LOCF). However, decreases
from baseline to week 12 in the mean MADRS score
were not significantly different between the two age
groups: -22.0 (SD = 17.8) points for patients aged 65-74
years, and -20.3 (SD = 14.1) points for patients ≥75
years; LOCF, p = 0.084 (ANCOVA, using age group as
factor, and baseline score as covariate). The mean score
of individual MADRS items for patients completing
open-label treatment indicates that the old-old patients
had slightly more residual symptoms at the end of the
open label phase of treatment, particularly in the form of
persistent inner tension and sleep disturbance (data not
shown).
Tolerability
AEs were reported by 135 (53.1%) of young-old patients
(n = 254) and 88 (58.3%) of old-old patients (n = 151).
Treatment-emergent AEs with an incidence ≥5% in
either age group that occurred during the open-label
period were nausea, headache, dizziness, diarrhoea, fati-
gue, hyperhidrosis and insomnia. The difference by age
was statistically significant only for hyperhidrosis [15
(5.9%) versus 2 (1.3%), respectively; p = 0.0372, Fisher’s
Exact test] and diarrhoea [17 (6.7%) versus 3 (2.0%),
respectively; p = 0.0348, Fisher’s Exact test]. In almost
all cases, spontaneously reported AEs were mild to
moderate. There was no significant difference in with-
drawal rates due to AEs between age groups (chi-square,
c
2 = 1.669, df = 1, p = 0.196). The most common AEs
leading to withdrawal for old-old patients (n = 151)
were nausea (14 patients), anxiety (7 patients), and
depression (5 patients) compared to nausea (9 patients),
anxiety (3 patients), and depression (3 patients), for
young-old patients. Of the 21 old-old patients who with-
drew due to an AE, there were 19 (out of 100) aged
from 75 to 79 years, 2 (out of 39) aged from 80 to 84
years, and 3 (out of 12) aged 85 years or above. Old-old
patients had a significantly higher incidence of serious
adverse events (SAEs) (12 out of 151 patients, 7.9%)
than young-old patients (5 out of 254 patients, 2.0%)
(Fisher’s Exact test, p = 0.008). A 75-year-old man with
a possibly-related SAE was hospitalized for 27 days due
to anxiety and suicidal ideation and subsequently
recovered.
Comparison by age in the 24-week randomized
continuation period
Withdrawals
Of the patients continuing into the double-blind period
of the study, 74 (40 escitalopram-treated and 34
placebo-treated patients) completed the study, corre-
sponding to completion rates of 80% (escitalopram) and
59% (placebo). The overall withdrawal rate excluding
relapses, was comparable for both age groups (7.6% for
Patients included   n=405
Withdrawn n=39
Adverse events                      n=25
Lack of efficacy                      n= 7
Consent withdrawn                n= 6
Protocol violation                    n= 0
Non-compliance                     n= 1  
Patients 65-74 years  n=254 Patients œ75 years n=151
Withdrawn n=33
Adverse events                      n=21
Lack of efficacy                      n= 5
Consent withdrawn                n= 2
Protocol violation                    n= 2
Non-compliance                     n= 3  
Patients 65-74 years  n=215 Patients œ75 years n=118
Withdrawn n=18
Adverse events                      n= 4
Lack of efficacy                      n=10
Consent withdrawn                n= 2
Non-compliance n= 1
Other n= 1  
Withdrawn n=10
Adverse events                      n= 3
Lack of efficacy                      n= 5
Consent withdrawn                n= 1
Non-compliance n= 1
Other n= 0  
Patients 65-74 years  randomised n=197 Patients œ75 years randomised   n=108
Withdrawn n=52
Adverse events                      n=7
Lack of efficacy                      n=37
Consent withdrawn                n= 3
Protocol violation                    n= 2
Non-compliance                     n= 3  
Withdrawn n=34
Adverse events                      n= 4
Lack of efficacy                      n=26
Consent withdrawn                n= 0
Protocol violation                    n= 2
Non-compliance                     n= 2  
Completed     n=145 Relapsed     n=37 Completed     n=45 Relapsed     n=26
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Figure 2 Patient disposition for the open label period and the
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events, CW: consent withdrawn, LoE: lack of efficacy, NC: non-
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young-old versus 7.4% for old-old): 5.9% for young-old
patients treated with escitalopram (total of 102 patients,
6 withdrawals not due to relapse), and 9.5% for young-
old patients treated with placebo (total of 95 patients,
9 withdrawals not due to relapse). For old-old patients,
the overall withdrawal rate excluding relapses, was 8.0%
for patients treated with escitalopram (total of 50
patients, 4 withdrawals not due to relapse), and 6.9% for
patients treated with placebo (total of 58 patients,
4 withdrawals not due to relapse).
Relapse prevention
Old-old patients randomised to double-blind treatment
had mean MADRS total scores of 5.8 (both treatment
groups) at week 12, compared to 5.0 for young-old
patients. For old-old patients, the proportion of patients
who relapsed within 24 weeks was significantly higher
on placebo (34.5%; 20 out of 58 patients) than on escita-
lopram (12.0%; 6 out of 50 patients) (chi-square test, c2
= 7.426, df = 1, p = 0.006). For young-old patients, the
proportion of patients who relapsed within 24 weeks
was also significantly higher on placebo (31.6%; 30 out
of 95 patients) than on escitalopram (6.9%; 7 out of 102
patients) (chi-square test, c2 = 19.698, df= 1, p < 0.001).
When comparing age groups, stratified by treatment,
there was no statistically significant difference in time to
relapse between young-old patients versus old-old
patients after randomisation to placebo (Figure 3, log-
rank test comparing the two placebo groups, c2 =
0.0404, df = 1, p = 0.841) or to escitalopram (Figure 3,
log-rank test comparing the two escitalopram groups,
c
2 = 1.1497, df = 1, p = 0.284). In the analysis of time
to relapse, based on the Cox proportional hazard model,
with treatment and age group as covariates, the
estimated hazard ratio for relapse on placebo versus
escitalopram was 4.4 (95% confidence interval: 2.4 to
8.1; chi-square test, c2 = 22.5, df = 1, p < 0.001),
whereas the effect of age group was not significant, with
a hazard ratio of 1.2 (95% confidence interval: 0.7 to 1.9,
chi-square test, c2 = 0.41, df = 1, p = 0.520) for old-old
versus young-old patients. The proportion of young-old
patients who relapsed based on the investigator’s judg-
ment was 29.7% (11/37) compared to 30.8% (8/26) of
old-old patients. The estimated hazard ratio for relapse
on placebo compared to escitalopram was 5.4 for young-
old patients and 3.2 for old-old patients. The proportion
of patients who remained in remission (MADRS ≤12) to
the end of the full study was higher on escitalopram
(89% for young-old patients versus 86% for old-old
patients) compared to placebo (61% for young-old
patients versus 57% for old-old patients) (LOCF). In the
sensitivity analysis, where the relapse criteria were
extended to include patients who met the DSM-IV
criteria for MDE, an additional 2 patients relapsed, both
in the placebo group.
Tolerability
During this period, AEs led to the withdrawal of 5
young-old patients and 4 old-old patients. The most
commonly reported AEs in young-old patients were
headache (8.1%), dizziness (5.6%), and diarrhoea (5.1%),
and in old-old patients, headache (3.7%), dizziness
(6.5%), hypertension (4.6%) and nasopharyngitis (4.6%).
SAEs were reported by 7 young-old and 6 old-old
patients. A 74-year-old man had a probably-related SAE
during treatment with placebo was hospitalised for 27
days due to relapse of depression and was withdrawn.
An 85-year-old woman with a possibly-related SAE dur-
ing treatment with escitalopram was hospitalised with
anaemia due to a gastric mucosal ulcer and subse-
quently recovered.
Discussion
The results of these post-hoc analyses indicate that
young-old and old-old patients with MDD have compar-
able rates of remission after open-label escitalopram,
and both age groups have statistically significantly lower
rates of relapse on escitalopram than on placebo.
To date, the few studies of pharmacological treatment
in this age group have primarily or exclusively included
patients in residential settings [19-21]. However, most
depressed patients aged at least 75 years live in the com-
munity. They tend to have less cognitive impairment
than nursing home residents [6]. Open-label treatment
with escitalopram was comparably effective in reducing
depression in young-old as in old-old patients, consistent
with the results of the meta-analysis of Gildengers et al.
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of 4.4 (chi-square test, df = 1, c2 = 22.5, p < 0.001), whereas the
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[22]. Notably, a significantly higher percentage of young-
old patients achieved complete remission, likely related
to the slightly higher level of symptoms at entry in the
old-old patients, particularly for MADRS items 3 to 8.
The response rates (77% and 83%) in both age groups
were greater than those reported in 2 placebo-controlled
trials of escitalopram in elderly patients (46% response)
[4,5], in which escitalopram failed to separate from pla-
cebo. Sneed et al. [23] also found higher response rates
in patients in comparator trials (60% response) com-
pared with placebo-controlled trials (46% response).
Hence, in the absence of a placebo control, these rates
of remission should not be construed as being entirely
related to escitalopram treatment. In addition to the
clinician-rated MADRS, the geriatric depression scale
was also used in the original study [12]. This patient
self-rating scale was only assessed at baseline, at rando-
misation and at last assessment. It is a validated scale
for the assessment of the health status of older people,
but does not directly assess symptoms of depression.
The pattern of AEs was similar in both age groups,
and to that previously seen with escitalopram in younger
adults [24]. Based on the incidence of adverse events
and withdrawals due to adverse events, old-old patients
tolerated treatment with escitalopram equally well as
young-old patients. During the 24-week relapse preven-
tion period, escitalopram was significantly more effica-
cious than placebo.
This study’s main strength is that, as a result of the
high remission rates during the open-label escitalopram
phase, there were relatively large numbers of patients in
both the young-old and old-old groups at the point of
randomisation, giving the study satisfactory statistical
power to detect differences in relapse rate and pattern
between them. The analysis by age group was, however,
retrospective, and its inclusion and exclusion criteria to
some extent limit the generalizability of its findings to
the depressed old-old population. A further limitation of
the study is that we did not investigate in detail the
effect of medical co-morbidities on outcomes. As
Reynolds et al. [25] note, the number and severity of
co-morbid medical illnesses moderate depression recur-
rence in older old depressed patient. Since medical
co-morbidities were comparable across the randomization
groups (Table 2), it is unlikely that medical co-morbidity
influenced any treatment benefit from escitalopram.
Conclusions
The study has clear and relevant implications for clinical
practice. The slightly higher percentage of young-old
patients achieving complete remission during the open-
label phase probably reflects the somewhat higher bur-
den of symptoms that old-old patients have at the start
of acute treatment. The comparable (and very low)
incidence of adverse events and of adverse event-related
withdrawals in old-old and young-old patients in both
phases of the study suggests that escitalopram is well-
tolerated by old-old depressed patients. Although
slightly fewer young-old patients on escitalopram
relapsed (6.9% vs 12% in the old-old group), the hazard
ratio was only slightly larger (1.2). It is therefore clear
that escitalopram is highly effective (compared with pla-
cebo) in preventing depressive relapse in old-old patients
who remit during acute escitalopram treatment, as
shown by the hazard ratio in this sub-group.
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